Immutep Ltd ADR (IMMP)

$0.39 -0.02 (-4.50%)
Market Cap 57.55M
Revenue (ttm) 6.69M
Net Income (ttm) -39.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -594.62%
Debt to Equity Ratio 0.01
Volume 319,700
Avg Vol 2,603,748
Day's Range N/A - N/A
Shares Out 147.37M
Stochastic %K 62%
Beta 2.21
Analysts Sell
Price Target $1.50

Company Profile

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 2 8315 7003
Fax: 61 2 8569 1880
Address:
Australia Square, Level 32 264 George Street, Sydney, Australia
revuelto
revuelto Jun. 26 at 8:03 PM
$IMMP appearances can be deceptive…that’s all I am going to say 😀
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jun. 26 at 1:26 PM
$IMMP r/s very next ….they have 3 months again
3 · Reply
revuelto
revuelto Jun. 23 at 3:15 PM
$IMMP one catalyst away from a catapult reaction 🥳🎉🤜
1 · Reply
11thestate
11thestate Jun. 22 at 2:23 PM
$IMMP investors: there is a new case filed against Immutep for overstating the outlook for its TACTI-004 Phase III lung cancer trial while allegedly concealing risks that the study could fail its interim review. If you held shares between 2025 and 2026, you can join the case and track recovery here https://11th.com/cases/immutep-investor-suit
0 · Reply
ToRni27
ToRni27 Jun. 22 at 2:02 PM
$IMMP when zero?
3 · Reply
TheUsualSuspect007
TheUsualSuspect007 Jun. 20 at 7:28 PM
$IMMP Pump up the jam, pump it up While your feet are stompin' And the jam is pumpin' Look ahead, the crowd is jumpin' Pump it up a little more!!! THIS AIN'T OVER YET!!!
1 · Reply
IFeelLike
IFeelLike Jun. 18 at 6:52 PM
$IMMP still sort of flabbergasted by ending tacti-004, hopefully a partial phase 3 can be started. Also guess IMP761 update did nothing for the sp because of uncertainty in tacti-004. I took 80% profit from some extra shares I bought after the dip, and sold mid april with the spike to 1 dollar. Seems it's gonna be a long ride again... with the extra shares I have, I would also be ok with a buyout of 1,5 or 2 billion.
1 · Reply
TheUsualSuspect007
TheUsualSuspect007 Jun. 18 at 9:45 AM
$IMMP
0 · Reply
allsign
allsign Jun. 17 at 7:34 PM
$IMMP
0 · Reply
ToRni27
ToRni27 Jun. 17 at 3:40 PM
$IMMP
0 · Reply
Latest News on IMMP
Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP

Mon, 29 Jun 2026 04:25:00 -0400 - 4 hours ago

Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm

Mon, 29 Jun 2026 03:15:00 -0400 - 5 hours ago

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP

Thu, 25 Jun 2026 10:00:00 -0400 - 3 days ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm

Thu, 25 Jun 2026 04:53:00 -0400 - 4 days ago

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm

Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP

Thu, 25 Jun 2026 04:52:00 -0400 - 4 days ago

Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Immutep Limited (IMMP)

Wed, 24 Jun 2026 09:24:00 -0400 - 4 days ago

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Immutep Limited (IMMP)

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines – IMMP

Tue, 23 Jun 2026 16:03:00 -0400 - 5 days ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines – IMMP

Portnoy Law Firm Announces Class Action on Behalf of Immutep Limited Investors

Tue, 23 Jun 2026 10:41:00 -0400 - 5 days ago

Portnoy Law Firm Announces Class Action on Behalf of Immutep Limited Investors

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm

Mon, 22 Jun 2026 04:05:00 -0400 - 7 days ago

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm

Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP

Mon, 22 Jun 2026 04:00:00 -0400 - 7 days ago

Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP

Thu, 18 Jun 2026 10:00:00 -0400 - 10 days ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm

Thu, 18 Jun 2026 09:39:00 -0400 - 10 days ago

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm

Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm

Wed, 17 Jun 2026 12:00:00 -0400 - 11 days ago

Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm

IMMUTEP LIMITED INVESTORS WITH LOSSES HAVE UNTIL JULY 6, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline

Wed, 17 Jun 2026 09:42:00 -0400 - 11 days ago

IMMUTEP LIMITED INVESTORS WITH LOSSES HAVE UNTIL JULY 6, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline

Immutep upgraded to Buy from Hold at Maxim

2026-06-17T12:06:14.000Z - 12 days ago

Immutep upgraded to Buy from Hold at Maxim

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines – IMMP

Tue, 16 Jun 2026 16:16:00 -0400 - 12 days ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines – IMMP

Portnoy Law Firm Announces Class Action on Behalf of Immutep Limited Investors

Tue, 16 Jun 2026 10:56:00 -0400 - 12 days ago

Portnoy Law Firm Announces Class Action on Behalf of Immutep Limited Investors

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm

Mon, 15 Jun 2026 09:40:00 -0400 - 13 days ago

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm

Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP

Mon, 15 Jun 2026 02:34:00 -0400 - 14 days ago

Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP

Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm

Sun, 14 Jun 2026 12:00:00 -0400 - 14 days ago

Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP

Thu, 11 Jun 2026 10:00:00 -0400 - 17 days ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP

Immutep Limited Faces Securities Fraud Lawsuit (IMMP)

2026-06-10T20:54:40.000Z - 18 days ago

Immutep Limited Faces Securities Fraud Lawsuit (IMMP)

IMMUTEP LIMITED INVESTORS WITH LOSSES HAVE UNTIL JULY 6, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline

Wed, 10 Jun 2026 09:47:00 -0400 - 18 days ago

IMMUTEP LIMITED INVESTORS WITH LOSSES HAVE UNTIL JULY 6, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline

IMMP Deadline Alert: Levi & Korsinsky Reminds Immutep Limited (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

Wed, 10 Jun 2026 09:00:00 -0400 - 19 days ago

IMMP Deadline Alert: Levi & Korsinsky Reminds Immutep Limited (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

IMMP Investor Alert - Immutep Limited Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit

Tue, 09 Jun 2026 21:06:00 -0400 - 19 days ago

IMMP Investor Alert - Immutep Limited Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit

IMMP UPCOMING DEADLINE: Levi & Korsinsky Alerts Immutep Limited Stockholders of Securities Class Action - Contact the Firm

Mon, 08 Jun 2026 16:00:00 -0400 - 20 days ago

IMMP UPCOMING DEADLINE: Levi & Korsinsky Alerts Immutep Limited Stockholders of Securities Class Action - Contact the Firm

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Sun, 07 Jun 2026 14:16:00 -0400 - 21 days ago

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Sat, 06 Jun 2026 09:16:00 -0400 - 22 days ago

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

IMMP Investors Have Opportunity to Lead Immutep Ltd. Securities Fraud Lawsuit

Fri, 05 Jun 2026 14:50:00 -0400 - 23 days ago

IMMP Investors Have Opportunity to Lead Immutep Ltd. Securities Fraud Lawsuit

Robbins LLP Reminds IMMP Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Class Action Against Immutep Limited

Fri, 05 Jun 2026 13:57:00 -0400 - 23 days ago

Robbins LLP Reminds IMMP Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Class Action Against Immutep Limited

ROSEN, LEADING INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Fri, 05 Jun 2026 11:38:00 -0400 - 23 days ago

ROSEN, LEADING INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Thu, 04 Jun 2026 23:18:00 -0400 - 24 days ago

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors Should Contact SueWallSt

Thu, 04 Jun 2026 17:33:00 -0400 - 24 days ago

IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors Should Contact SueWallSt

Immutep to present positive interim Phase I data for IMP761

2026-06-04T13:15:39.000Z - 24 days ago

Immutep to present positive interim Phase I data for IMP761

IMMP

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Immutep Limited (IMMP)

Thu, 04 Jun 2026 09:14:00 -0400 - 24 days ago

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Immutep Limited (IMMP)

Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026

Jun 4, 2026, 8:00 AM EDT - 25 days ago

Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026

IMMP

IMMP DEADLINE: Levi & Korsinsky Reminds Immutep Limited Investors of Upcoming Securities Class Action Deadline

Wed, 03 Jun 2026 09:00:00 -0400 - 26 days ago

IMMP DEADLINE: Levi & Korsinsky Reminds Immutep Limited Investors of Upcoming Securities Class Action Deadline

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Tue, 02 Jun 2026 23:13:00 -0400 - 26 days ago

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

Tue, 02 Jun 2026 16:00:00 -0400 - 26 days ago

IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

IMMP INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

Tue, 02 Jun 2026 12:49:00 -0400 - 26 days ago

IMMP INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm

Tue, 02 Jun 2026 09:00:00 -0400 - 27 days ago

IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm

ROSEN, A LONGSTANDING FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Mon, 01 Jun 2026 23:13:00 -0400 - 27 days ago

ROSEN, A LONGSTANDING FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 6, 2026 in Immutep Limited Lawsuit - IMMP

Mon, 01 Jun 2026 14:33:00 -0400 - 27 days ago

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 6, 2026 in Immutep Limited Lawsuit - IMMP

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

Mon, 01 Jun 2026 11:52:00 -0400 - 27 days ago

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

IMMP DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

Sun, 31 May 2026 09:04:00 -0400 - 4 weeks ago

IMMP DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

IMMP CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

Sat, 30 May 2026 08:36:00 -0400 - 4 weeks ago

IMMP CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Sat, 30 May 2026 07:13:00 -0400 - 4 weeks ago

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 6, 2026 in Immutep Limited Lawsuit - IMMP

Fri, 29 May 2026 09:00:00 -0400 - 4 weeks ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 6, 2026 in Immutep Limited Lawsuit - IMMP

IMMP UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

Fri, 29 May 2026 08:19:00 -0400 - 4 weeks ago

IMMP UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

ROSEN, A LEADING LAW FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Thu, 28 May 2026 14:45:00 -0400 - 4 weeks ago

ROSEN, A LEADING LAW FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

IMMUTEP LIMITED (IMMP) INVESTOR ALERT Investors With Large Losses in Immutep Limited Should Contact Bernstein Liebhard LLP To Discuss Their Rights

May 7, 2026, 9:03 AM EDT - 7 weeks ago

IMMUTEP LIMITED (IMMP) INVESTOR ALERT Investors With Large Losses in Immutep Limited Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Immutep receives noncompliance notification from Nasdaq

2026-04-30T14:06:28.000Z - 2 months ago

Immutep receives noncompliance notification from Nasdaq

3 Penny Stocks to Watch Now, 4/16/26

2026-04-16T18:52:15.000Z - 2 months ago

3 Penny Stocks to Watch Now, 4/16/26

BIRD

Why Is Immutep Stock (IMMP) Up Today?

2026-04-15T13:01:30.000Z - 2 months ago

Why Is Immutep Stock (IMMP) Up Today?

Immutep granted Orphan Drug Designation for eftilagimod alfa

2026-04-15T12:23:31.000Z - 2 months ago

Immutep granted Orphan Drug Designation for eftilagimod alfa

Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma

Apr 15, 2026, 8:00 AM EDT - 2 months ago

Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma

Immutep sees progress from Phase I study of LAG-3 agonist for autoimmune disease

2026-03-19T12:28:18.000Z - 3 months ago

Immutep sees progress from Phase I study of LAG-3 agonist for autoimmune disease

Immutep Limited Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 16, 2026, 8:03 AM EDT - 3 months ago

Immutep Limited Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Why Did Investors Lose Faith In Immutep Stock (IMMP) Today?

2026-03-14T00:11:00.000Z - 3 months ago

Why Did Investors Lose Faith In Immutep Stock (IMMP) Today?

Immutep downgraded to Hold from Buy at Maxim

2026-03-13T16:52:01.000Z - 3 months ago

Immutep downgraded to Hold from Buy at Maxim

Immutep says IDMC recommends discontinuation for TACTI-004 Phase III study

2026-03-13T12:12:46.000Z - 3 months ago

Immutep says IDMC recommends discontinuation for TACTI-004 Phase III study

Immutep downgraded to Neutral from Outperform at Baird

2026-03-13T09:35:41.000Z - 3 months ago

Immutep downgraded to Neutral from Outperform at Baird

Immutep downgraded to Market Perform from Outperform at Citizens

2026-03-13T08:45:13.000Z - 3 months ago

Immutep downgraded to Market Perform from Outperform at Citizens

Immutep Quarterly report: H1 2026

Feb 24, 2026, 6:00 PM EST - 4 months ago

Immutep Quarterly report: H1 2026

Immutep initiated with an Outperform at Citizens

2026-02-17T09:55:08.000Z - 4 months ago

Immutep initiated with an Outperform at Citizens

Immutep achieves 50% enrollment in global TACTI-004 Phase III trial

2026-02-06T13:06:35.000Z - 5 months ago

Immutep achieves 50% enrollment in global TACTI-004 Phase III trial

Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC

Feb 6, 2026, 8:00 AM EST - 5 months ago

Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC

Immutep reports Q2 cash receipts from customers A$4,000

2026-01-29T13:21:20.000Z - 5 months ago

Immutep reports Q2 cash receipts from customers A$4,000

Immutep Quarterly Activities Report Q2 FY26

Jan 29, 2026, 8:00 AM EST - 5 months ago

Immutep Quarterly Activities Report Q2 FY26

Immutep Earnings release: Q2 2026

Jan 28, 2026, 6:00 PM EST - 5 months ago

Immutep Earnings release: Q2 2026

Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study

Dec 22, 2025, 8:00 AM EST - 6 months ago

Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study

India's Dr Reddy's signs licensing pact to sell Immutep's cancer drug

Dec 8, 2025, 2:34 AM EST - 7 months ago

India's Dr Reddy's signs licensing pact to sell Immutep's cancer drug

Immutep Transcript: AGM 2025

Nov 26, 2025, 7:30 PM EST - 7 months ago

Immutep Transcript: AGM 2025

Immutep Slides: FY 2025

Nov 26, 2025, 7:30 PM EST - 7 months ago

Immutep Slides: FY 2025

Immutep Transcript: Bell Potter Healthcare Conference 2025

Nov 19, 2025, 5:00 PM EST - 7 months ago

Immutep Transcript: Bell Potter Healthcare Conference 2025

Immutep Earnings release: Q1 2026

Oct 28, 2025, 6:00 PM EDT - 8 months ago

Immutep Earnings release: Q1 2026

Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025

Oct 20, 2025, 8:01 AM EDT - 9 months ago

Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025

Immutep Annual report: H2 2025

Oct 9, 2025, 10:00 AM EDT - 9 months ago

Immutep Annual report: H2 2025

Immutep Annual report: H2 2025

Oct 9, 2025, 10:00 AM EDT - 9 months ago

Immutep Annual report: H2 2025

Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025

Sep 8, 2025, 8:00 AM EDT - 10 months ago

Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025

Immutep Quarterly Activities Report Q4 FY25

Jul 30, 2025, 8:00 AM EDT - 11 months ago

Immutep Quarterly Activities Report Q4 FY25

Immutep Earnings release: Q4 2025

Jul 29, 2025, 6:00 PM EDT - 11 months ago

Immutep Earnings release: Q4 2025

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer

Jul 29, 2025, 8:00 AM EDT - 11 months ago

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer

Immutep Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 11:40 AM EDT - 1 year ago

Immutep Transcript: Jefferies Global Healthcare Conference 2025

Immutep Slides: Corporate Presentation

Jun 1, 2025, 6:00 PM EDT - 1 year ago

Immutep Slides: Corporate Presentation

Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

May 27, 2025, 8:00 AM EDT - 1 year ago

Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

Immutep Earnings release: Q3 2025

Apr 28, 2025, 6:00 PM EDT - 1 year ago

Immutep Earnings release: Q3 2025

Immutep to Participate in Upcoming Investor Conferences

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Immutep to Participate in Upcoming Investor Conferences

Immutep Quarterly report: H1 2025

Feb 25, 2025, 6:00 PM EST - 1 year ago

Immutep Quarterly report: H1 2025

Immutep Quarterly Activities Report Q2 FY25

Jan 31, 2025, 8:00 AM EST - 1 year ago

Immutep Quarterly Activities Report Q2 FY25

Immutep Earnings release: Q2 2025

Jan 30, 2025, 6:00 PM EST - 1 year ago

Immutep Earnings release: Q2 2025

Immutep Transcript: Baird's Biotech Discovery Series

Dec 19, 2024, 10:15 AM EST - 1 year ago

Immutep Transcript: Baird's Biotech Discovery Series

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Dec 17, 2024, 8:00 AM EST - 1 year ago

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

Dec 12, 2024, 8:15 AM EST - 1 year ago

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

Immutep Transcript: AGM 2024

Nov 21, 2024, 6:30 PM EST - 1 year ago

Immutep Transcript: AGM 2024

Immutep Slides: FY 2024

Nov 21, 2024, 6:30 PM EST - 1 year ago

Immutep Slides: FY 2024

Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

Nov 14, 2024, 8:15 AM EST - 1 year ago

Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

Immutep Quarterly Activities Report Q1 FY25

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Immutep Quarterly Activities Report Q1 FY25

Immutep Annual report: H2 2024

Oct 22, 2024, 3:30 AM EDT - 1 year ago

Immutep Annual report: H2 2024

Immutep Annual report: H2 2024

Oct 22, 2024, 3:30 AM EDT - 1 year ago

Immutep Annual report: H2 2024

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 10, 2024, 8:00 AM EDT - 1 year ago

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

Immutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

Sep 16, 2024, 8:00 AM EDT - 1 year ago

Immutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

Immutep Slides: Corporate Presentation

Aug 21, 2024, 2:00 AM EDT - 2 years ago

Immutep Slides: Corporate Presentation

Immutep Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Aug 14, 2024, 8:30 AM EDT - 2 years ago

Immutep Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Immutep Quarterly Activities Report Q4 FY24

Jul 31, 2024, 8:00 AM EDT - 2 years ago

Immutep Quarterly Activities Report Q4 FY24

Immutep Slides: Study Update Presentation

Jul 11, 2024, 7:00 PM EDT - 2 years ago

Immutep Slides: Study Update Presentation

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

Jul 11, 2024, 6:40 PM EDT - 2 years ago

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

Jul 3, 2024, 8:00 AM EDT - 2 years ago

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

Immutep Slides: Study Result Presentation

Jun 26, 2024, 7:00 PM EDT - 2 years ago

Immutep Slides: Study Result Presentation

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

Jun 25, 2024, 8:00 AM EDT - 2 years ago

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

Immutep successfully completes institutional placement and institutional component of entitlement offer

Jun 5, 2024, 6:00 AM EDT - 2 years ago

Immutep successfully completes institutional placement and institutional component of entitlement offer

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

Jun 2, 2024, 8:38 PM EDT - 2 years ago

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

May 15, 2024, 8:00 AM EDT - 2 years ago

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

Positive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

May 2, 2024, 8:00 AM EDT - 2 years ago

Positive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

Immutep Quarterly Activities Report Q3 FY24

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Immutep Quarterly Activities Report Q3 FY24

Immutep Earnings release: Q3 2024

Apr 28, 2024, 8:00 PM EDT - 2 years ago

Immutep Earnings release: Q3 2024

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

Apr 18, 2024, 8:00 AM EDT - 2 years ago

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Apr 17, 2024, 8:00 AM EDT - 2 years ago

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Mar 5, 2024, 8:00 AM EST - 2 years ago

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Immutep Quarterly Activities Report Q2 FY24

Jan 30, 2024, 8:00 AM EST - 2 years ago

Immutep Quarterly Activities Report Q2 FY24

Immutep Earnings release: Q2 2024

Jan 30, 2024, 2:30 AM EST - 2 years ago

Immutep Earnings release: Q2 2024

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

Jan 4, 2024, 8:00 AM EST - 2 years ago

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Dec 21, 2023, 8:00 AM EST - 2 years ago

Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

Dec 7, 2023, 8:00 AM EST - 2 years ago

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

Nov 22, 2023, 8:00 AM EST - 2 years ago

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Nov 9, 2023, 8:00 AM EST - 2 years ago

Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

revuelto
revuelto Jun. 26 at 8:03 PM
$IMMP appearances can be deceptive…that’s all I am going to say 😀
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jun. 26 at 1:26 PM
$IMMP r/s very next ….they have 3 months again
3 · Reply
revuelto
revuelto Jun. 23 at 3:15 PM
$IMMP one catalyst away from a catapult reaction 🥳🎉🤜
1 · Reply
11thestate
11thestate Jun. 22 at 2:23 PM
$IMMP investors: there is a new case filed against Immutep for overstating the outlook for its TACTI-004 Phase III lung cancer trial while allegedly concealing risks that the study could fail its interim review. If you held shares between 2025 and 2026, you can join the case and track recovery here https://11th.com/cases/immutep-investor-suit
0 · Reply
ToRni27
ToRni27 Jun. 22 at 2:02 PM
$IMMP when zero?
3 · Reply
TheUsualSuspect007
TheUsualSuspect007 Jun. 20 at 7:28 PM
$IMMP Pump up the jam, pump it up While your feet are stompin' And the jam is pumpin' Look ahead, the crowd is jumpin' Pump it up a little more!!! THIS AIN'T OVER YET!!!
1 · Reply
IFeelLike
IFeelLike Jun. 18 at 6:52 PM
$IMMP still sort of flabbergasted by ending tacti-004, hopefully a partial phase 3 can be started. Also guess IMP761 update did nothing for the sp because of uncertainty in tacti-004. I took 80% profit from some extra shares I bought after the dip, and sold mid april with the spike to 1 dollar. Seems it's gonna be a long ride again... with the extra shares I have, I would also be ok with a buyout of 1,5 or 2 billion.
1 · Reply
TheUsualSuspect007
TheUsualSuspect007 Jun. 18 at 9:45 AM
$IMMP
0 · Reply
allsign
allsign Jun. 17 at 7:34 PM
$IMMP
0 · Reply
ToRni27
ToRni27 Jun. 17 at 3:40 PM
$IMMP
0 · Reply
rispi
rispi Jun. 16 at 6:41 PM
$IMMP ohhhh pumpers!!!
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jun. 16 at 5:39 AM
$IMMP and so JPMorgan too out of this investment.. 🙈
0 · Reply
24DV4NC3D
24DV4NC3D Jun. 12 at 7:57 PM
$IMMP ⚡️WHAT DID I SAY?!⚡️ STOCK OF THE DAY - VOLUME >>>>> #LISTEN! <<<<< >> HIGH POTENTIAL << >>>>>>> LISTEN! <<<<<<<
0 · Reply
GaryGherkins
GaryGherkins Jun. 11 at 1:55 PM
$IMMP is the management team hiding out in a kangaroo pouch? time to attend another pharma conference to announce some pre clinical testing on primates for crying out loud; when you have an ongoing phase 3 that could have helped the sp
1 · Reply
Messerschmittbf109
Messerschmittbf109 Jun. 11 at 3:58 AM
$IMMP r/s and merger next ….I don’t see other possibility
1 · Reply
bylocehi
bylocehi Jun. 8 at 4:57 PM
$IMMP
2 · Reply
Duskfall
Duskfall Jun. 7 at 7:47 PM
let's go back to this list. I also mentioned that I try to look for these a month in advance before the move. 3 hit and two didn't make a move, at least not yet.. $SES 1.03👉 1.45 $CRMD 7.64👉8.97 $TNYA 0.6490👉0.84 $BIVI +/- $IMMP ❌
0 · Reply
sunrisetiger
sunrisetiger Jun. 6 at 8:34 AM
$IMMP If a stock's closing bid price is below $1.00 for 30 consecutive business days. Has a deficiency notice been issued yet?
1 · Reply
Faisalfft
Faisalfft Jun. 5 at 7:23 PM
$IMMP Is there an analysis of the stock? Will it rise or continue to fall?
2 · Reply
hendo7179
hendo7179 Jun. 5 at 8:34 AM
$IMMP well, closer to 10c than $1.
1 · Reply
Hurtadogoalkeeper
Hurtadogoalkeeper Jun. 5 at 7:49 AM
$IMMP Yesterday news. https://www.immutep.com/immutep-to-present-positive-interim-phase-i-data-for-imp761-a-first-in-class-lag-3-agonist-antibody-at-eular-2026/
0 · Reply
focafoca99
focafoca99 Jun. 5 at 12:10 AM
$IMMP legal notice urges shareholders to contact SueWallSt for a securities class action over the TACTI-004 trial collapse.
0 · Reply